Article

Generic versions of oxybutynin gain approval for OAB

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.

Related Videos
Anne Pelletier Cameron, MD, FRCSC, FPMRS, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Medcast series
Modern medical office interior with computer and examination table | Image Credit: © New Africa - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.